NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in pt, en, de, nl, it, es, et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, da, ro, sv, fr, and other parts: Adding translations: et, lt, it, fr, hr, el, en, sk, fi, pl, hu, nl, cs, lv, ga, sl, es, bg, mt, pt, da, ro, de, sv,) |
(Changed label, description and/or aliases in en, pt: Fixing missing labels.) |
||
| label / pt | label / pt | ||
NEUROTERA .: Para a introdução no mercado de novos agentes terapêuticos contra co-morbilidades oculares e cerebrais associadas à Paramiloidose | |||
| label / en | label / en | ||
NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis | |||
Revision as of 18:35, 24 August 2022
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,221.0 Euro
0 references
1,136,308.0 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references